Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03075527 | A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma | terminated | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03148327 | Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy | terminated | Phase 1 / Phase 2 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 2 | Jul 16, 2026 |
| clinicaltrials |
| NCT03425331 | Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC | terminated | Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06028373 | A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas | terminated | Phase 1 | 38 | Antengene Biologics LimitedINDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07152821 | Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma(BATTMAN) | terminated | Phase 3 | 21 | Canadian Cancer Trials GroupNETWORK | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07441330 | Evaluation of Data Obtained From Three Common Imaging Techniques: Positron Emission Tomography (PET-CT), Breast Ultrasound, and Magnetic Resonance Imaging (MRI) After Neoadjuvant Chemotherapy in Patients With Breast Cancer | terminated | N/A | 42 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04698564 | Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging | terminated | Phase 2 | 4 | University of Maryland, BaltimoreOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06528093 | A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy | terminated | Phase 1 | 8 | Boehringer IngelheimINDUSTRY | 6 | Jul 15, 2026 | clinicaltrials |
| NCT04469504 | Preoperative Prehabilitation for Sarcopenic Patients Prior to Pancreatic Surgery for Cancer(PSOAS) | terminated | N/A | 6 | University Hospital, LilleOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05828589 | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | terminated | Phase 1 | 51 | BeOne MedicinesINDUSTRY | 4 | Jul 14, 2026 | clinicaltrials |
| NCT02200042 | Radiation Therapy vs. Observation Following Gemcitabine and Cisplatin for Inoperable Localized Liver Cancer | terminated | Phase 3 | 1 | NRG OncologyOTHER | 2 | Jul 13, 2026 | clinicaltrials |
| NCT03874858 | A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia(DANTE) | terminated | Phase 2 | 135 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04933695 | A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment(CodeBreaK201) | terminated | Phase 2 | 42 | AmgenINDUSTRY | 10 | Jul 13, 2026 | clinicaltrials |
| NCT05067777 | Massage for Prostate Cancer-Related Fatigue (mPROSTATE)(mPROSTATE) | terminated | Phase 2 | 28 | University of UtahOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | terminated | Phase 1 / Phase 2 | 14 | TCR2 TherapeuticsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05478837 | Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma(PNOC018) | terminated | Phase 1 | 4 | University of California, San FranciscoOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06158100 | Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) | terminated | Phase 1 | 2 | Antonio M Jimenez JimenezOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06470451 | Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL(FLASH2) | terminated | Phase 3 | 70 | SoligenixINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT03439046 | Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant(BioItaLEE) | terminated | Phase 3 | 287 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT03766126 | Lentivirally Redirected CD123 Autologous T Cells in AML | terminated | Phase 1 | 22 | University of PennsylvaniaOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT03114319 | Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 227 | Novartis PharmaceuticalsINDUSTRY | 9 | Jul 9, 2026 | clinicaltrials |
| NCT04318327 | BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma | terminated | Phase 1 | 96 | Novartis PharmaceuticalsINDUSTRY | 4 | Jul 9, 2026 | clinicaltrials |
| NCT04331067 | Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer | terminated | Phase 1 / Phase 2 | 15 | Washington University School of MedicineOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT04855136 | Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma(KarMMa-7) | terminated | Phase 1 | 21 | CelgeneINDUSTRY | 2 | Jul 9, 2026 | clinicaltrials |
| NCT06376253 | A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers | terminated | Phase 1 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT04527900 | The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach | terminated | Phase 2 | 2 | University of Maryland, BaltimoreOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05705791 | Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial 166Holmium Radiation Therapy in Combination With Atezolizumab and Bevacizumab for Non Resectable Hepatocellular Carcinoma(HOLMBRAVE) | terminated | N/A | 10 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06585488 | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification | terminated | Phase 1 | 47 | BeOne MedicinesINDUSTRY | 5 | Jul 8, 2026 | clinicaltrials |
| NCT00640978 | Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT04216472 | Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations | terminated | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT04824859 | A Geriatric Assessment Electronic Platform for Older Patients With Cancer (eGAP - Electronic Geriatric Assessment Platform)(eGAP) | terminated | N/A | 21 | University of RochesterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06466187 | A Study of SGN-MesoC2 in Advanced Solid Tumors | terminated | Phase 1 | 19 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | Jul 7, 2026 | clinicaltrials |
| NCT04037527 | Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities | terminated | Phase 1 | 9 | Wake Forest University Health SciencesOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05731947 | Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 41 | Syndax PharmaceuticalsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06120504 | A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers | terminated | Phase 1 | 22 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | Jul 6, 2026 | clinicaltrials |
| NCT06254495 | A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers | terminated | Phase 1 | 58 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 6 | Jul 6, 2026 | clinicaltrials |
| NCT04809766 | Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | terminated | Phase 1 | 9 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05660967 | Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma(EPCORE DLBCL-3) | terminated | Phase 2 | 111 | GenmabINDUSTRY | 12 | Jul 2, 2026 | clinicaltrials |
| NCT01871571 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer | terminated | Phase 2 | 17 | University of Southern CaliforniaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05571839 | A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 | 41 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 6 | Jul 1, 2026 | clinicaltrials |
| NCT04751383 | Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma | terminated | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 2 | Jun 30, 2026 | clinicaltrials |
| NCT04788043 | Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma | terminated | Phase 2 | 8 | Ranjana AdvaniOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT04887935 | Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer | terminated | Phase 1 | 5 | Washington University School of MedicineOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05204290 | Study of Combined Decompressive Spine Radiosurgery and Pembrolizumab | terminated | Early Phase 1 | 1 | Wake Forest University Health SciencesOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05627323 | CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma | terminated | Phase 1 | 1 | Chimeric TherapeuticsINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06191250 | --SuPERIOR Trial-- | terminated | Phase 2 | 10 | University Health Network, TorontoOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06779669 | Use of Alternative and Complementary Medicine by Colorectal Cancer Patients(ALTERNATIVCCR) | terminated | N/A | 217 | University Hospital, LimogesOTHER | 1 | Jun 29, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 16, 2026source: clinicaltrials